HLA variation and antigen presentation in COVID-19 and SARS-CoV-2 infection

Curr Opin Immunol. 2022 Jun:76:102178. doi: 10.1016/j.coi.2022.102178. Epub 2022 Mar 25.

Abstract

The extraordinary variation of the human leukocyte antigen (HLA) molecules is critical for diversifying antigen presentation to T cells. Coupled with the rise of novel strains and rapidly evolving immune evasion by SARS-CoV-2 proteins, HLA-mediated immunity in COVID-19 is critically important but far from being fully understood. A growing number of studies have found the association of HLA variants with different COVID-19 outcomes and that HLA genotypes associate with differential immune responses against SARS-CoV-2. Prediction studies have shown that mutations in multiple viral strains, most concentrated in the Spike protein, affect the affinity between these mutant peptides and HLA molecules. Understanding the impact of this variation on T-cell responses is critical for comprehending the immunogenic mechanisms in both natural immunity and vaccine development.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antigen Presentation
  • COVID-19*
  • Epitopes, T-Lymphocyte
  • HLA Antigens / genetics
  • Histocompatibility Antigens Class I / genetics
  • Histocompatibility Antigens Class II
  • Humans
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus / genetics

Substances

  • Epitopes, T-Lymphocyte
  • HLA Antigens
  • Histocompatibility Antigens Class I
  • Histocompatibility Antigens Class II
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2